Takayuki Takimoto

Dr. Takayuki Takimoto

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Respiratory Investigation
Verified
Journal Article
Closed access
KAKoji Azuma
Koji Azuma
TTTakayuki Takimoto
Takayuki Takimoto
TKTakahiko Kasai
Takahiko Kasai
MHMasaki Hirose
Masaki Hirose
KHKazuyoshi Hatsuda
Kazuyoshi Hatsuda
YIYoshikazu Inoue
Yoshikazu Inoue

30 November 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
TAToru Arai
Toru Arai
TTTakayuki Takimoto
Takayuki Takimoto
NTNaoko Takeuchi
Naoko Takeuchi
SMShojiro Minomo
Shojiro Minomo
TKTomoko Kagawa
Tomoko Kagawa
YIYoshikazu Inoue
Yoshikazu Inoue
Background: This study aimed to clarify the prognostic value of the neutrophil-to-lymphocyte ratio (NLR) in patients with acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF). Methods: Eighty-six patients diagnosed with AE-IPF were included in this single-center retrospective study. The NLR was calculated by dividing the peripheral neutrophil count by the peripheral lymphocyte count. The cut-off values of the NLR for predicting 90-day survival were determined using receiver operating characteristic curve analysis. Oxygenation deterioration on days 4 and 8 relative to that on day 1 was clinically defined. The prognostic value of NLR was evaluated using Cox proportional hazard regression analysis. Results: The cut-off value of day-1, day-4, and day-8 NLRs for predicting 90-day survival was 12.13, 14.90, and 10.56, respectively. A higher day-1 NLR was a significant predictor of a poor prognosis in univariate and multivariate analyses. Survival was significantly better in patients without oxygenation deterioration on days 4 and 8 than in those with deterioration. Day-4 and day-8 NLR could predict 90-day survival in patients without oxygenation deterioration. Conclusions: Day-1 NLR was a useful predictor of 90-day survival in AE-IPF. Further, monitoring day-4 and day-8 NLRs and evaluating oxygenation deterioration may be useful for managing AE-IPF.

16 June 2023 in Respiratory Investigation
Verified
Journal Article
Closed access
TTTakayuki Takimoto
Takayuki Takimoto
AYAtsushi Yanagisawa
Atsushi Yanagisawa
TAToru Arai
Toru Arai
YIYoshikazu Inoue
Yoshikazu Inoue

18 June 2020 in Respirology Case Reports
Verified
Journal Article
Open access
PDF file
TTTakayuki Takimoto
Takayuki Takimoto
TKTomoko Kagawa
Tomoko Kagawa
KTKazunobu Tachibana
Kazunobu Tachibana
TAToru Arai
Toru Arai
YIYoshikazu Inoue
Yoshikazu Inoue
Benralizumab is an interleukin‐5 (IL‐5) receptor α‐directed cytolytic monoclonal antibody that reduces rapid and nearly complete depletion of eosinophils by enhancing antibody‐dependent cell‐mediated cytotoxicity. The depletion of eosinophilic inflammation is expected to reduce mucus hypersecretion and mucoid impaction. A 75‐year‐old non‐smoking female had been treated for uncontrolled bronchial asthma with multiple drugs. Treatment with benralizumab was initiated after the asthma attack; however, four months later, she developed massive atelectasis in the left lung leading to the tracheal deviation, to the extent that nasal high‐flow therapy was required. The laboratory data showed elevated neutrophil count, whereas blood eosinophils were almost completely depleted. The thick mucus was removed by bronchofiberscopy and the atelectasis was completely resolved. No exacerbation has been observed for nine months after discontinuation of benralizumab and initiation of erythromycin. This is the first documented case that developed atelectasis by mucoid impaction during treatment with anti‐IL‐5 receptor antibody.

1 January 2023 in JMA Journal
Verified
Journal Article
Open access
TTTakayuki Takimoto
Takayuki Takimoto
HSHiromitsu Sumikawa
Hiromitsu Sumikawa
TAToru Arai
Toru Arai
YIYoshikazu Inoue
Yoshikazu Inoue
Pleuroparenchymal fibroelastosis (PPFE) is a rare interstitial lung disease that is characterized by predominant upper lobe fibrosis and pleural thickening. In this report, we present an unusual case of idiopathic PPFE with left vocal cord paralysis that developed repeated aspiration pneumonia. Vocal cord paralysis is a rare complication of PPFE, and two mechanisms can be proposed: 1) Fibrous adhesion of the recurrent laryngeal nerve to the chest wall can cause stretching of the nerve. 2) Traction or compression of the recurrent laryngeal nerve due to the distortion of the tracheobronchial tree can cause paralysis of the vocal cord. Finally, to reduce the risk of aspiration pneumonia, laryngoscopic evaluation of the vocal cord is recommended in patients with PPFE with hoarseness and dysphagia for early intervention.

13 October 2024 in Respiratory Investigation
Verified
Journal Article
Closed access
KKKensuke Kanaoka
Kensuke Kanaoka
TAToru Arai
Toru Arai
TTTakayuki Takimoto
Takayuki Takimoto
MMMitsuhiro Moda
Mitsuhiro Moda
RSRyota Shintani
Ryota Shintani
SSShigeki Shimizu
Shigeki Shimizu